ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Mutated Diffuse Midline Gliomas

The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.

Related Keywords

North Carolina ,United States ,University Of Pennsylvania ,Pennsylvania ,University Of North Carolina ,Philadelphia ,Charlotte ,Stephen Bagley ,Ashley Sumrall ,Hospital Of The University Pennsylvania ,University Of North Carolina Chapel Hill ,Abramson Cancer Center ,Atrium Health Carolinas Medical Center ,Atrium Health Levine Cancer Institute ,Internal Medicine ,Medical Oncology ,North Carolina Chapel Hill ,Phase Studies Pave ,Data Shows Tolerable Safety Profile ,Onc201 ,Patients With H3k27m Mutated Diffuse Midline Glioma ,Action Trial ,Nct05580562 ,D ,Osce ,Naacp ,The Hospital Of University Pennsylvania ,